Tocilizumab in Severe and Critical COVID-19 Pneumonia: Streamlining the Mixed Signals
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Fu Y, Cheng Y, Wu Y
. Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools. Virol Sin. 2020; 35(3):266-271.
PMC: 7090474.
DOI: 10.1007/s12250-020-00207-4.
View
2.
Kyriakopoulos C, Ntritsos G, Gogali A, Milionis H, Evangelou E, Kostikas K
. Tocilizumab administration for the treatment of hospitalized patients with COVID-19: A systematic review and meta-analysis. Respirology. 2021; 26(11):1027-1040.
PMC: 8661720.
DOI: 10.1111/resp.14152.
View
3.
Parasher A
. COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment. Postgrad Med J. 2020; 97(1147):312-320.
PMC: 10017004.
DOI: 10.1136/postgradmedj-2020-138577.
View
4.
McKenzie M, Lee Y, Mathew J, Anderson M, Vo A, Akinyele S
. Tocilizumab for the Critically Ill With Severe COVID-19: A Community Hospital Case Series. J Pharm Pract. 2021; 35(4):587-592.
DOI: 10.1177/08971900211002353.
View
5.
Chavez-Ocana S, Bravata-Alcantara J, Cortes-Ortiz I, Reyes-Sandoval A, Garcia-Machorro J, Herrera-Gonzalez N
. Parameters to Predict the Outcome of Severe and Critical COVID-19 Patients when Admitted to the Hospital. J Clin Med. 2023; 12(4).
PMC: 9959673.
DOI: 10.3390/jcm12041323.
View